An oncogene regulating chromatin favors response to immunotherapy-Reference-Cited by-全球学者库

An oncogene regulating chromatin favors response to immunotherapy

Published:2024-01-09 Issue:1 Volume:13 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ying Leqian¹²,Hu Zhangmin¹,Lu Yi³,Tao Qing¹,Xiong Fen¹,Shu Yongqian⁴,Yang Yufei¹,Qiao Xuehan¹,Peng Chen¹,Jiang Yuchun¹,Han Miao¹,Xu Min⁵,Li Xiaoqin¹,Wang Deqiang¹^ORCID

Affiliation:

1. Department of Oncology, Digestive Disease Institute&Cancer Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, China

2. Department of Oncology, Zhong-Da Hospital, Medicine School, Southeast University, Nanjing, China

3. Department of Oncology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, China

4. Department of Oncology, Jiangsu Province Hospital & The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

5. Department of Gastroenterology, Digestive Disease Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, China

Funder

The Natural Science Foundation of Jiangsu Province

Key Medical Research Projects of Jiangsu Provincial Health Commission

Chinese Society Of Clinical Oncology Youth Committee

China Postdoctoral Science Foundation

Science and Technology Planning Social Development Project

Medical Education Collaborative Innovation Fund

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2024.2303195

Reference46 articles.

1. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

2. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

3. Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma

4. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

5. Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer